Department of Health Sciences, University of Florence, Florence, Italy.
Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Eur J Immunol. 2024 Nov;54(11):e2451140. doi: 10.1002/eji.202451140. Epub 2024 Sep 3.
The characteristic expansion of T CD38/HLA-DRCD8 lymphocytes observed in hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) proved able to distinguish HLH/MAS from sepsis and systemic juvenile idiopathic arthritis. However, the performance of this marker in differentiating HLH/MAS from other pediatric febrile conditions with similar clinical onset and yet entirely different treatments remains unexplored. CD38/HLA-DRCD8 frequencies measured in the peripheral fresh blood of pediatric patients attended for suspicion of HLH/MAS were retrospectively recorded and clinical characteristics were retrieved. CD38/HLA-DRCD8 frequencies in HLH/MAS patients (15 patients; median: 22.0%, IQR: 11.0-49.0%) were compared with those who presented febrile conditions other-than-HLH (28 patients; median: 13.0%, IQR: 3.9-28.7%; p = 0.24). HLH and non-HLH patients were subsequently regrouped based on the presence of an identified infection (22 patients; median: 27.0%, IQR: 15.2-72.1%) and compared with those without infections (21 patients; median: 7.6%, IQR: 3.7-24.3%; p = 0.0035). CD38/HLA-DRCD8 percentages were significantly higher only in the infection group compared with the noninfection one, with a patent pathogen-specific expansion in Epstein-Barr virus primoinfection and visceral leishmaniasis regardless of the presence of HLH. CD38/HLA-DRCD8 frequencies do not appear as an HLH-specific marker as they naturally expand in other clinical situations that are common in childhood and may mimic HLH initial presentation.
噬血细胞性淋巴组织细胞增生症(HLH)和巨噬细胞活化综合征(MAS)中观察到的 T CD38/HLA-DRCD8 淋巴细胞特征性扩增能够将 HLH/MAS 与脓毒症和全身幼年特发性关节炎区分开来。然而,这种标志物在区分 HLH/MAS 与其他具有相似临床发病但治疗方法完全不同的儿科发热性疾病方面的性能仍未得到探索。回顾性记录了因疑似 HLH/MAS 而就诊的儿科患者外周新鲜血液中 CD38/HLA-DRCD8 的频率,并检索了临床特征。将 HLH/MAS 患者(15 例;中位数:22.0%,IQR:11.0-49.0%)与表现为非 HLH 发热性疾病的患者(28 例;中位数:13.0%,IQR:3.9-28.7%;p=0.24)进行比较。随后根据是否存在明确的感染将 HLH 和非 HLH 患者重新分组(22 例;中位数:27.0%,IQR:15.2-72.1%),并与无感染的患者(21 例;中位数:7.6%,IQR:3.7-24.3%;p=0.0035)进行比较。仅在感染组中,CD38/HLA-DRCD8 百分比明显高于非感染组,并且在 EBV 初次感染和内脏利什曼病中存在明显的病原体特异性扩增,而与 HLH 的存在无关。CD38/HLA-DRCD8 频率似乎不是 HLH 的特异性标志物,因为它们在儿科常见的其他临床情况下自然扩增,可能会模拟 HLH 的初始表现。